| Turner Syndrome
Humatrope vs Norditropin
Side-by-side clinical, coverage, and cost comparison for turner syndrome.Deep comparison between: Humatrope vs Norditropin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNorditropin has a higher rate of injection site reactions vs Humatrope based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Norditropin but not Humatrope, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Humatrope
Norditropin
At A Glance
SC injection
Daily
Recombinant human growth hormone
SC injection
Daily
Recombinant human growth hormone
Indications
- Somatotropin deficiency
- Turner Syndrome
- Short Stature Homeobox Deficiency
- Growth retardation
- Noonan Syndrome
- Turner Syndrome
- Prader-Willi Syndrome
Dosing
Somatotropin deficiency (pediatric) 0.18 mg/kg/week to 0.3 mg/kg/week divided into equal doses given 6 or 7 days per week by SC injection.
Somatotropin deficiency (adult) Non-weight based: initiate at approximately 0.2 mg/day (range 0.15-0.3 mg/day), increase every 1-2 months by 0.1-0.2 mg/day per patient requirements; weight-based (not for obese patients): initiate at 0.006 mg/kg/day up to 0.0125 mg/kg/day; daily SC injection.
Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses given 6 or 7 days per week by SC injection.
Short Stature Homeobox Deficiency 0.35 mg/kg/week (0.05 mg/kg/day) by SC injection.
Growth retardation Idiopathic Short Stature: up to 0.37 mg/kg/week; Small for Gestational Age: up to 0.47 mg/kg/week; divided into equal doses given 6 or 7 days per week by SC injection.
Pediatric GHD 0.17-0.24 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.
Noonan Syndrome Up to 0.46 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.
Turner Syndrome, SGA, ISS Up to 0.47 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.
Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.
Adult GHD (non-weight-based) Initiate at approximately 0.2 mg/day SC (range 0.15-0.3 mg/day); increase every 1-2 months by 0.1-0.2 mg/day based on clinical response and IGF-1 concentrations.
Adult GHD (weight-based) Initiate at 0.004 mg/kg/day SC; increase to a maximum of 0.016 mg/kg/day; not recommended for obese patients.
Contraindications
- Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Prader-Willi syndrome in pediatric patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
- Active malignancy
- Known hypersensitivity to somatropin or any excipient in HUMATROPE
- Active proliferative or severe non-proliferative diabetic retinopathy
- Closed epiphyses in pediatric patients
- Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
- Active malignancy
- Hypersensitivity to somatropin or any excipient of NORDITROPIN
- Active proliferative or severe non-proliferative diabetic retinopathy
- Pediatric patients with closed epiphyses
Adverse Reactions
Most common (>=5%) Edema, arthralgia, paresthesia, myalgia, pain, peripheral edema, headache, hypertension, rhinitis, back pain (adults); hypothyroidism, allergic reaction, arthralgia, bone disorder, injection site pain (pediatric GHD).
Serious Increased mortality in acute critical illness, fatalities in Prader-Willi syndrome, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, severe hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, pancreatitis, lipoatrophy.
Postmarketing Anaphylactic reactions, angioedema, increase in size or number of cutaneous nevi, gynecomastia, pancreatitis, new-onset type 2 diabetes mellitus, osteonecrosis, leukemia.
Most common (>=5%, adult onset GHD) Peripheral edema, edema, arthralgia, leg edema, myalgia, non-viral infection, paraesthesia, skeletal pain, headache, bronchitis, flu-like symptoms, hypertension, gastroenteritis, increased sweating, abnormal glucose tolerance, laryngitis, type 2 diabetes mellitus
Serious Increased mortality in acute critical illness, sudden death in pediatric PWS patients, neoplasms, intracranial hypertension, severe hypersensitivity reactions, fluid retention, slipped capital femoral epiphysis, pancreatitis
Postmarketing Anaphylactic reactions, angioedema, increase in cutaneous nevi, hypothyroidism, gynecomastia, hyperglycemia, osteonecrosis, increased blood alkaline phosphatase, decreased serum T4, pancreatitis, leukemia
Pharmacology
Somatropin is a recombinant human growth hormone that binds dimeric GH receptors on target tissue cell membranes, triggering intracellular signal transduction and induction of GH-dependent proteins (IGF-1, IGFBP-3, acid-labile subunit), with direct and IGF-1-mediated effects including stimulation of chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, and lipolysis, thereby promoting skeletal and linear growth in pediatric patients with GH deficiency.
Recombinant human growth hormone (somatropin) binds to dimeric GH receptors on target tissue cell membranes, triggering intracellular signal transduction and induction of GH-dependent proteins including IGF-1, IGFBP-3, and acid-labile subunit, which stimulate chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, lipolysis, and skeletal linear growth via effects on epiphyses of long bones.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Humatrope
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (10/12)
Norditropin
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (4/12) · Qty limit (9/12)
UnitedHealthcare
Humatrope
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Norditropin
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (1/8) · Qty limit (4/8)
Humana
Humatrope
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Norditropin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Growth Hormone Deficiency
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Norditropin.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HumatropeView full Humatrope profile
NorditropinView full Norditropin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.